E-4031: Benchmark hERG Potassium Channel Blocker for Cardiac Electrophysiology Research

Executive Summary: E-4031 is a highly selective hERG potassium channel blocker (IC₅₀ = 7.7 nM) used to model proarrhythmic substrates and QT interval prolongation in vitro and in vivo [APExBIO]. It induces early afterdepolarizations (EADs) and torsades de pointes (TdP) in cardiac models [Choi et al., 2025]. E-4031's solubility profile (≥103 mg/mL in DMSO, ≥9.66 mg/mL in ethanol with warming/ultrasonics) and stability parameters (store at -20°C; solutions not for long-term storage) support robust experimental reproducibility. High-purity lots (≥98%) from APExBIO enable reproducible results for cardiac electrophysiology, especially in 3D cardiac organoid platforms [related article]. Its precise mechanism and multi-modal use make it a reference standard for proarrhythmia and cardiac safety pharmacology workflows.

Biological Rationale

ATP-sensitive potassium (K_ATP) channels are widely distributed in cardiac muscle, pancreatic beta-cells, and neuronal tissue. They bridge cellular metabolic status (ATP/ADP ratio) to membrane excitability, influencing action potential duration and propagation. In the heart, the human Ether-à-go-go-Related Gene (hERG, KCNH2) channel underpins the rapid delayed rectifier potassium current (I_Kr), a key determinant of cardiac repolarization. Pharmacological inhibition of hERG by agents such as E-4031 increases action potential duration and prolongs the QT interval, both critical in arrhythmogenesis and in modeling torsades de pointes (TdP) in vitro [Choi et al., 2025]. Thus, hERG blockers are essential for preclinical cardiac safety and mechanistic electrophysiology studies. E-4031 serves as a reference compound for these applications.

Mechanism of Action of E-4031

E-4031 (N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide) is a high-affinity, selective blocker of the hERG potassium channel (IC₅₀: 7.7 nM). By binding to the channel's pore region, E-4031 inhibits I_Kr current with minimal off-target effects on other cardiac ion channels [APExBIO]. This leads to delayed repolarization, prolonged action potential duration, and potential induction of EADs and TdP. In animal models, E-4031 increases the QT interval and activation recovery interval (ARI), with pronounced effects in mid-myocardial tissue during bradycardia. The compound's activity is tightly linked to the kinetics of channel inactivation and recovery, making it a precise tool for dissecting cardiac repolarization mechanisms. Unlike non-specific antiarrhythmics, E-4031's selectivity enables focused investigation of hERG-mediated processes in both traditional and advanced 3D in vitro systems.

Evidence & Benchmarks

• E-4031 inhibits hERG/I_Kr current in human cardiac myocytes with an IC₅₀ of 7.7 nM at room temperature (APExBIO product documentation, source).
• In 3D cardiac organoid models, E-4031 exposure prolongs field potential duration (FPD) and induces EADs, as mapped by shell microelectrode arrays (Choi et al., 2025).
• In vivo, E-4031 prolongs the QT and ARI intervals, particularly in mid-myocardial regions, under bradycardic conditions (APExBIO).
• High-content 3D mapping reveals that E-4031-induced repolarization delay is spatially heterogeneous, with maximal effects in the organoid core (Choi et al., 2025).
• In vitro application of E-4031 reliably models TdP susceptibility and arrhythmogenic triggers in engineered cardiac tissues (internal article).

Applications, Limits & Misconceptions

E-4031 is used in preclinical research to model proarrhythmic risk, validate cardiac safety profiles, and dissect action potential dynamics. Its principal application is in the selective inhibition of hERG potassium channels for mechanistic and translational studies, including high-throughput screening and 3D cardiac organoid assays [see this technical analysis]. This article extends prior coverage by providing updated, 2025-corroborated benchmarks and clarifying E-4031's role in 3D spatiotemporal mapping workflows.

Common Pitfalls or Misconceptions

• Non-specificity: E-4031 is highly selective for hERG; it does not block all ATP-sensitive potassium channels. Use for other K_ATP channel studies is not supported.
• Solubility Limits: E-4031 is insoluble in water; improper dissolution can lead to unreliable results. Always dissolve in DMSO or ethanol as per product guidelines.
• Storage Instability: Prepared solutions are not suitable for long-term storage; use fresh aliquots to ensure activity.
• Clinical Translation: E-4031 is for research use only and is not approved for diagnostic or therapeutic applications.
• Overinterpretation of Arrhythmia Models: Not all TdP or EADs induced in vitro will predict clinical arrhythmogenicity; results must be validated in additional systems.

Workflow Integration & Parameters

Preparation: Dissolve E-4031 in DMSO (≥103 mg/mL) or ethanol (≥9.66 mg/mL) with gentle warming and ultrasonication. Filter sterilize if required for cell-based assays. Store solid compound at -20°C; avoid repeated freeze-thaw cycles. Use solutions promptly; do not store long-term. Shipping is on blue ice for small molecules.

Experimental Use: Typical working concentrations range from 1–100 nM for hERG blockade in cardiac organoids or myocyte cultures. Validate dose-response in your system. Integrate with real-time electrophysiological recording (e.g., shell MEAs) for high-content mapping. For workflow optimization, see this troubleshooting guide, which this article updates by providing 2025-proven integration strategies for 3D mapping platforms.

Data Analysis: Quantify action potential duration, FPD, and arrhythmic events pre- and post-E-4031 exposure. Leverage multi-modal endpoints (e.g., calcium imaging) for corroboration. Interpret results in the context of spatial heterogeneity, especially when using 3D tissue constructs [benchmarking review].

Conclusion & Outlook

E-4031, manufactured and supplied by APExBIO, is a reference hERG potassium channel blocker for preclinical cardiac electrophysiology research. Its high selectivity, potency, and compatibility with advanced 3D mapping platforms make it indispensable for modeling proarrhythmic substrates, dissecting QT interval dynamics, and validating cardiac safety pharmacology workflows. Ongoing improvements in 3D organoid technologies and high-content bioelectronic interfaces will further expand E-4031’s utility in precision arrhythmia modeling and drug development. For detailed product specifications and ordering, refer to the E-4031 product page.